<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04155814</url>
  </required_header>
  <id_info>
    <org_study_id>BXU537298</org_study_id>
    <secondary_id>QSC202208</secondary_id>
    <nct_id>NCT04155814</nct_id>
  </id_info>
  <brief_title>Bioequivalence Study Assessing Iron Sucrose or Venofer® in Healthy Adult Subjects</brief_title>
  <official_title>Bioequivalence Study Assessing a Single Dose of Iron Sucrose Injection (Baxter) or a Single Dose of Venofer® Injection in Healthy Adult Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Baxter Healthcare Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Quotient Sciences</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Baxter Healthcare Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates the bioequivalence, pharmacokinetic (PK) profile, and safety and
      tolerability of Iron Sucrose (Test Product) relative to that of Venofer® in healthy subjects.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 19, 2019</start_date>
  <completion_date type="Actual">December 18, 2019</completion_date>
  <primary_completion_date type="Actual">December 18, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cmax(delta)</measure>
    <time_frame>Hours before injection (24, 12, 0.25); Minutes after end of injection (1, 5, 10, 15, 30, 45); Hours after end of injection (1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 10, 12, 16, 24, 36)</time_frame>
    <description>Maximum concentration (Cmax) across all time points for the delta difference between Total Iron (TI) and Transferrin Bound Iron (TBI). This is a PK test parameter to compare bioequivalence of two drug products.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-t(delta)</measure>
    <time_frame>Hours before injection (24, 12, 0.25); Minutes after end of injection (1, 5, 10, 15, 30, 45); Hours after end of injection (1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 10, 12, 16, 24, 36)</time_frame>
    <description>Area under the concentration curve (AUC) from time zero to last time of quantifiable concentration (Tlast) for the delta difference in AUC0-t between TI and TBI. This is a PK test parameter to compare bioequivalence of two plasma drug products.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cmax</measure>
    <time_frame>Hours before injection (24, 12, 0.25); Minutes after end of injection (1, 5, 10, 15, 30, 45); Hours after end of injection (1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 10, 12, 16, 24, 36)</time_frame>
    <description>Maximum concentration (Cmax) across all time points for both TI and TBI. This is a PK test parameter to compare bioequivalence of two plasma drug products.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC0-t</measure>
    <time_frame>Hours before injection (24, 12, 0.25); Minutes after end of injection (1, 5, 10, 15, 30, 45); Hours after end of injection (1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 10, 12, 16, 24, 36)</time_frame>
    <description>Area under the concentration-time curve (AUC) from time zero to last sample time for both TI and TBI. This is a PK test parameter to compare bioequivalence of two drug products.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC0-inf</measure>
    <time_frame>Hours before injection (24, 12, 0.25); Minutes after end of injection (1, 5, 10, 15, 30, 45); Hours after end of injection (1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 10, 12, 16, 24, 36)</time_frame>
    <description>Area under the concentration-time curve (AUC) from time zero extrapolated to infinity for both TI and TBI. This is a PK test parameter to compare bioequivalence of two drug products.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax</measure>
    <time_frame>Hours before injection (24, 12, 0.25); Minutes after end of injection (1, 5, 10, 15, 30, 45); Hours after end of injection (1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 10, 12, 16, 24, 36)</time_frame>
    <description>Time of occurrence of Cmax (Tmax) for both TI and TBI. This is a PK test parameter to compare bioequivalence of two drug products.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t1/2</measure>
    <time_frame>Hours before injection (24, 12, 0.25); Minutes after end of injection (1, 5, 10, 15, 30, 45); Hours after end of injection (1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 10, 12, 16, 24, 36)</time_frame>
    <description>Terminal phase half-life (t1/2) for both TI and TBI. This is a PK test parameter to compare bioequivalence of two drug products.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vz</measure>
    <time_frame>Hours before injection (24, 12, 0.25); Minutes after end of injection (1, 5, 10, 15, 30, 45); Hours after end of injection (1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 10, 12, 16, 24, 36)</time_frame>
    <description>Volume of distribution (Vz) for both TI and TBI. This is a PK test parameter to compare bioequivalence of two drug products.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CL</measure>
    <time_frame>Hours before injection (24, 12, 0.25); Minutes after end of injection (1, 5, 10, 15, 30, 45); Hours after end of injection (1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 10, 12, 16, 24, 36)</time_frame>
    <description>Total body clearance (CL) for extravascular administration calculated by Dose/AUC for both TI and TBI. This is a PK test parameter to compare bioequivalence of two drug products.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of AUCex</measure>
    <time_frame>Hours before injection (24, 12, 0.25); Minutes after end of injection (1, 5, 10, 15, 30, 45); Hours after end of injection (1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 10, 12, 16, 24, 36)</time_frame>
    <description>AUC0-inf due to extrapolation (AUCex) from Tlast to infinity calculated by: 100 × (AUC0-inf-AUC0-t)/AUC0-inf (%AUCex) for both TI and TBI. This is a PK test parameter to compare bioequivalence of two drug products.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with clinically significant findings on physical examinations</measure>
    <time_frame>Day -28 (Screening) through Day 10 (Follow-up)</time_frame>
    <description>Any clinically significant abnormality will also be reported as an AE.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with clinically significant changes to ECG parameters</measure>
    <time_frame>Day -28 (Screening), Day -2, 0.25 hours before injection, and 6, 24 and 36 hours after end of injection</time_frame>
    <description>Any clinically significant abnormality will also be reported as an AE.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with occurrence of adverse events (AEs)</measure>
    <time_frame>Day -28 (Screening) through Day 30</time_frame>
    <description>An AE is any untoward medical occurrence in a subject that occurs either before dosing (referred to as a pre-dose AE) or once a medicinal product has been administered, including occurrences which are not necessarily caused by or related to that product.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with occurrence of adverse events of special interest</measure>
    <time_frame>Day -28 (Screening) through Day 30</time_frame>
    <description>Special interest items includes hypersensitivity reactions including anaphylactic/anaphylactoid reactions.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">196</enrollment>
  <condition>Bioequivalance</condition>
  <arm_group>
    <arm_group_label>Iron Sucrose Injection</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IV injection (5 mL), delivered over 5 minutes to subjects that have been fasted for a minimum of 10 hours.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Venofer Injection</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>IV injection (5 mL), delivered over 5 minutes to subjects that have been fasted for a minimum of 10 hours.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Iron Sucrose Injection</intervention_name>
    <description>USP 100 mg/5 mL (20 mg/mL), solution for IV injection, 100 mg unit dose strength</description>
    <arm_group_label>Iron Sucrose Injection</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Venofer Injection</intervention_name>
    <description>(Iron Sucrose 20 mg/mL), solution for IV injection, 100 mg unit dose strength</description>
    <arm_group_label>Venofer Injection</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy males or non-pregnant, non-lactating healthy females

          -  Age 18 to 55 years of age (both inclusive)

          -  Must, in the opinion of the investigator, be in good health based upon medical
             history, physical examination (including vital signs and ECGs) and clinical laboratory
             tests assessed at the time of screening

          -  Body mass index (BMI) of 18.0 to 32.0 kg/m2 and a minimum body weight of 40 kg, or if
             outside the range, considered not clinically significant by the investigator

          -  Ferritin levels not less than the lower limit of normal as defined by clinical
             laboratory reference ranges for female and male subjects at screening only

          -  Transferrin Saturation (TSAT) not less than the lower limit of normal as defined by
             clinical laboratory reference ranges for female and male subjects at screening only

          -  Hemoglobin levels not less than the lower limit of normal as defined by clinical
             laboratory reference ranges for male and female subjects

          -  Must agree to use an adequate method of contraception:

               -  For male subjects: Subjects willing to follow approved birth control methods (a
                  double barrier method) for the duration of the study as judged by the
                  investigator(s), such as condom with spermicide, condom with diaphragm, or
                  abstinence. Subjects should also not donate sperm during this time.

               -  For female subjects: Female subjects of childbearing potential, defined as a
                  woman &lt; 55 years of age who has not had a partial or full hysterectomy or
                  oophorectomy, must have a negative urine pregnancy test at screening and a
                  negative beta human chorionic gonadotropin (β-hCG) pregnancy test at admission.
                  Subjects of childbearing potential must use a medically acceptable means of
                  contraception during their participation in the study

          -  Non-smoker, defined as: Non-smoker for &gt; 12 months (i.e., subject has not smoked or
             used any tobacco product, e-cigarettes, and nicotine replacement products for the 12
             months prior to the start of the study) based on subject report.

          -  Must be willing and able to comply with all study requirements

          -  Must be able to understand a written informed consent, which must be obtained prior to
             initiation of study procedures

        Exclusion Criteria:

          -  Hypersensitivity to iron sucrose or iron products

          -  Presence or history of clinically significant allergy requiring treatment, as judged
             by the investigator. Hay fever is allowed unless it is active

          -  Serious adverse reaction or serious hypersensitivity to any drug or the formulation
             excipients

          -  Clinically significant abnormal biochemistry, hematology or urinalysis as judged by
             the investigator

          -  History of iron deficiency within 6 months prior to screening

          -  History of anemia within 6 months prior to screening

          -  Suspicion of iron overload as evidenced by both elevated serum TSAT and serum ferritin
             levels

          -  History of hemochromatosis

          -  Bleeding disorders, acute bleeding or recently documented hemorrhage

          -  Females with history of hypermenorrhea or menorrhagia

          -  History of cardiovascular, pulmonary, hepatic, renal, gastrointestinal, endocrine,
             immunological, dermatological, neurological or psychiatric disease or disorder, as
             judged by the investigator

          -  Must not have significant serious skin disease, including rash, food allergy, eczema,
             psoriasis, or urticaria

          -  Female subjects who are currently pregnant, lactating, or planning to become pregnant
             during the study period

          -  Positive hepatitis B surface antigen (HBsAg), hepatitis C virus antibody (HCV Ab) or
             human immunodeficiency virus (HIV) results

          -  Positive drugs of abuse test result or history of drug abuse in the past 6 months
             based on subject report

          -  Positive urinalysis test for alcohol at screening or history of alcoholism in the past
             6 months based on subject report

          -  Regular alcohol consumption in males &gt;21 units per week and females &gt;14 units per week
             (1 unit = ½ pint beer, or a 25 mL shot of 40% spirit, 1.5 to 2 Units = 125 mL glass of
             wine, depending on type)

          -  Administration of an injectable drug within 14 days prior to drug administration in
             this study

          -  Subjects who are taking, or have taken, any prescribed or over-the-counter drug (other
             than up to 4 g per day acetaminophen in the 14 days before IMP administration,
             hormonal contraceptives, or hormone replacement therapy. Exceptions may apply on a
             case by case basis, if considered not to interfere with the objectives of the study,
             as agreed by the PI and sponsor's medical monitor

          -  Use of iron supplements (including iron-containing multivitamins) within 3 months of
             the first dose IMP administration in the study

          -  Have poor venous access that limits phlebotomy

          -  Subjects who have donated blood (1 unit = 450 mL) within 3 months prior to the first
             dose of the study drug and plasma within 7 days prior to the first dose of the study
             drug.

          -  Subjects who have received any IMP in a clinical research study within 5 half-lives or
             within 30 days prior to first dose. However, in no event, shall the time between last
             receipt of IMP and first dose be less than 30 days

          -  Subjects who are study site employees, or immediate family members of a study site or
             sponsor employee

          -  Subjects who have previously been enrolled in this study

          -  Failure to satisfy the investigator of fitness to participate for any other reason
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Baxter Investigational Site</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33126</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>November 5, 2019</study_first_submitted>
  <study_first_submitted_qc>November 5, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 7, 2019</study_first_posted>
  <last_update_submitted>January 16, 2020</last_update_submitted>
  <last_update_submitted_qc>January 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ferric Oxide, Saccharated</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

